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A selective mono-N-arylation strategy of amidines under Chan-
Lam conditions is described. During the reaction optimization
phase, the isolation of a mononuclear Cu(II) complex provided
unique mechanistic insight into the operation of Chan-Lam
mono-N-arylation. The scope of the process is demonstrated,
and then applied to access the first mono-N-arylated analogues
of pentamidine. Sub-micromolar activity against kinetoplastid
parasites was observed for several analogues with no cross-
resistance in pentamidine and diminazene-resistant trypano-
some strains and against Leishmania mexicana. A fluorescent
mono-N-arylated pentamidine analogue revealed rapid cellular
uptake, accumulating in parasite nuclei and the kinetoplasts.
The DNA binding capability of the mono-N-arylated pentam-
idine series was confirmed by UV-melt measurements using AT-
rich DNA. This work highlights the potential to use Chan-Lam
mono-N-arylation to develop therapeutic leads against diami-
dine-resistant trypanosomiasis and leishmaniasis.
Amidines are essential functional groups used throughout
medicinal chemistry.[1] The versatility of this motif arises from
their ability to form strong, bifurcated hydrogen bonds and
electrostatic interactions with a range of hydrogen bond
acceptors and conjugate bases.[2] In addition, modulating the
basicity of the amidine group (pKaH~13–14) alters the overall
physicochemical properties, potency, and selectivity of amidine-
containing therapeutics.[3] A prominent exemplar of this
approach is the development of the DNA-binding antiparasitic
pentamidine for the treatment of early-stage Trypanosoma
brucei gambiense-related human African trypanosomiasis (HAT)
or sleeping sickness,[4] AIDS-related pneumocystis pneumonia,
and leishmaniasis (Scheme 1a).[5] The broader importance of
diamidine antiparasitics is further exemplified by their use as
the main treatment for animal African trypanosomiasis (AAT),
caused by the related parasite Trypanosoma congolense, which
has a billion-dollar adverse impact on emerging economies.[6]
Poor oral bioavailability and the emergence of pentamidine-
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Scheme 1. (a) Amidines in antiparasitic agents. (b) Selective amidine mono-
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binding analogues (Scheme 1a).[7] Modification of the essential
amidine moiety is a nascent strategy to by-pass resistance
mechanisms in these parasites by modulating the affinity of
diamidines for key drug transporters in T. brucei[8] [e. g., TbAT1/
P2 aminopurine transporters,[9] High Affinity Pentamidine Trans-
porter (HAPT)[10]].[11] However, expedient synthetic access to
mono-N-arylated amidines has been hampered by the lack of
robust synthetic methodology suitable for structure-activity
relationship profiling:[12] existing Pinner-style methodology[13] is
unsuited to this challenge due to forcing reaction conditions
limiting functional group tolerance, and the lack of chemo-
selective control leading to competing di/tri-N-arylation.[14] By
virtue of readily-available starting materials, Pd-[15] and Cu-
catalyzed cross couplings (e.g., Ullmann,[3c,16] Chan-Lam[17])
provide the opportunity to selectively access mono-N-function-
alised amidine analogues.
Here we report a mild and chemoselective approach to
exemplify amidine mono-N-arylation via the optimization of a
Chan-Lam strategy (Scheme 1b). We expand the substrate
scope and demonstrate its application to access, for the first
time, mono-N-arylated pentamidines as anti-parasitic leads for
treatment of HAT, AAT, and leishmaniasis.[18]
A prominent challenge of amidine functionalization is
controlling mono- vs. di/tri-N-arylation.[17b,19] Although selective
amidine N-arylation strategies have been reported, these are
embedded within cascade processes alongside C  H activation
events.[17b,20] As such, the identification of reaction variables
which influence mono- vs. di/tri-N-arylation was first estab-
lished.
Under standard Chan-Lam conditions,[21] a model system
using benzamidine (1) and PhB(OH)2 gave 73% overall yield
and ca. 4 :1 selectivity in favor of the mono- (2) vs. N,N’-
diarylated product 3 (Entry 1, Table 1). Using an excess of PhB
(OH)2 led to 82% total yield with ca. 9 :1 selectivity for 3
(Entry 2), which suggested selective mono-N-arylation vs. N,N’-
diarylation is possible by controlling reagent stoichiometry. No
tri-N-functionalization products were observed. Vantourout’s
B(OH)3-based conditions were less effective (Entry 3).
[22] Li’s
NaOPiv-based conditions provided a high conversion and ca.
40 :1 selectivity for 2 (Entry 4);[17b] however, further exploration
of these conditions did not improve the conversion to 2
(Table S5). The observation of a pronounced base effect led to a
focused screen and identification of K2CO3 as the optimal
additive (Entries 5–9). This screen ultimately provided selective
mono-N-arylation set of conditions using 20 mol% Cu(OAc)2
giving 2 in 81% isolated yield and without any observable
generation of 3 (Entry 10).
In contrast to our experience with other Chan-Lam
processes,[22–23] reactions using 1 and K2CO3 produced a purple
precipitate within the first 5 minutes of the reaction (Figure S3).
X-ray crystallographic analysis revealed a C2-symmetric mono-
nuclear Cu(II) complex 4 (Scheme 2a) consisting of a bidentate
carbonate ligand and two monodentate benzamidines. This
unique complex suggests that K2CO3 plays a dual role in this
system, acting both as a ligand and base. A dual ligand/base
role has been speculated in some Cu(OAc)2-based Chan-Lam
reactions;[24] however, structural information has been limited to
the observation of a single tetranuclear Cu(II) complex.[22]
Exposing 4 to PhB(OH)2 in i-PrOH afforded 2 in 61% yield,
suggesting 4 is a reaction-relevant intermediate (Scheme 2a).
The role of 4 was further investigated by EPR analysis of
reaction mixtures. No EPR signals were observed when [Cu-
(OAc)2] · 2H2O was treated with K2CO3 or PhB(OH)2. In contrast, a
paramagnetic species was observed upon addition of 1 (Fig-
ure S2). This suggests that 1 is responsible for paddlewheel
denucleation, consistent with mechanistic proposals for the
Chan-Lam amination.[22,25] Complex 4 could form after paddle-
wheel denucleation via ligand exchange processes at, for
example, putative Cu(II) complexes 5 and 6 (Scheme 2b).
Supplementary to our main aim of using a Chan-Lam
strategy for the late-stage mono-N-arylation of pentamidine,
the generality of the approach was assessed using a range of
amidines and arylboronic acids, all of which exclusively formed
mono-N-arylated products (2–29, Scheme 3a, Table S6). The use
of 20 mol% Cu(OAc)2 was comparable to stoichiometric Cu-
(OAc)2; however, for expediency, the latter was used across the
series based on the faster reaction time (see Table 1, Entries 7
and 9) with comparable yields afforded for both processes (see
yields for catalytic reactions in parentheses).
Both mono- and bisamidines are known Cu-chelators,[26]
which could hamper the wider utility of this approach to mono-
Table 1. Reaction development.[a]
Entry Conditions 2/3 (%)[b]
1[c] Cu(OAc)2 (100 mol%), Et3N, CH2Cl2, RT, 16 h 59/14
2[c,d] Cu(OAc)2 (100 mol%), Et3N, CH2Cl2, RT, 16 h 8/74
3 Cu(OAc)2 (100 mol%), B(OH)3, CH2Cl2, RT, 16 h 45/11
4[d] Cu(OAc)2 (100 mol%), NaOPiv, DMF, 50 °C, 16 h 81/2
5 Cu(OAc)2 (100 mol%), K2CO3, CH2Cl2, RT, 16 h 40/8
6 Cu(OAc)2 (100 mol%), K2CO3, MeOH, RT, 16 h 59/2
7[c] Cu(OAc)2 (100 mol%), K2CO3, i-PrOH, RT, 2 h 83/5
8 Cu(OAc)2 (50 mol%), K2CO3, i-PrOH, 50 °C, 24 h 76/2
9[c] Cu(OAc)2 (20mol%), K2CO3, i-PrOH, 50 °C, 24h 81/0
[a] Using 2 :1 1 : PhB(OH)2 and 2 equiv. of additive unless noted. [b]
Determined by HPLC analysis using standard concentration curves of 2
and 3. [c] Isolated yield on 1 mmol scale. [d] 1 : PhB(OH)2=1 :2. [e] 1 : PhB
(OH)2=1 :1.2.
Scheme 2. (a) Structure of Cu(II) complex 4. (b) Chan-Lam bond formation
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N-arylate pentamidine for structure-activity-relationship (SAR)
profiling. Indeed, standard Chan-Lam conditions failed to
deliver any N-arylation of pentamidine. Gratifyingly, our reaction
conditions were leveraged to directly access a series of
exclusively mono-N-arylated pentamidines (30–36, Scheme 3b)
in a single step from pentamidine.[5b,27]
This focused series covered analogues ranging from unsub-
stituted (30), mono-substituted (31–33) and disubstituted
aromatics (34), a quinolone (35), and the bulky fluorescent
analogue (36) suitable for cellular uptake studies.
Compounds (30–36) were then tested for activity against
three kinetoplastid parasite species that are commonly treated
with pentamidine (T. brucei, L. mexicana) or diminazene
aceturate (T. congolense) (Table 2).[28] EC50 values ranged from
0.19 μM to 1.1 μM, with 33 exhibiting the greatest potency
followed by 34. Indeed, for T. brucei, the SAR was quite flat,
with quinoline (35) and biphenyl (31) analogues displaying
similar EC50s to the phenyl analogue (30).
The compounds were also tested against the related
kinetoplastid parasites L. mexicana and T. congolense. Here, 33
displayed >2-fold and >3-fold higher activity compared to
pentamidine against T. congolense and L. mexicana, respectively.
The SAR profile was considerably less flat than for T. brucei, with
33 being 4.6-fold and 19.2-fold more active than 30 against T.
congolense and L. mexicana, respectively.
Scheme 3. (a) Scope of mono-N-arylation. Yields in parentheses for reactions at 50 °C for 24 h using 20 mol% Cu(OAc)2. (b) Library of monoarylated
pentamidine derivatives. [a] Isolated as the corresponding TFA salt.
Table 2. Activity of mono-N-aryl pentamidine analogues 30–36 against kinetoplastid parasites.
Entry Compound T. b. brucei T. congolense L. mexicana
EC50 [μM; n=3] RF t-test EC50 [μM; n=3] RF t-test EC50
[μM; n=4]WT B48 WT DA-Res
1 30 1.10�0.07 1.31�0.02 1.19 0.042 2.94�0.10 3.26�0.01 1.11 0.037 12.7�0.7
2 31 0.91�0.02 0.86�0.02 0.94 0.10 n.d. n.d. – – 2.12�0.07
3 32 0.65�0.03 0.37�0.006 0.57 0.0007 1.26�0.03 1.56�0.06 1.23 0.012 9.71�0.56
4 33 0.19�0.003 0.28�0.006 1.47 0.0002 0.64�0.02 0.75�0.003 1.23 0.0008 0.66�0.04
5 34 0.51�0.004 0.51�0.02 1.01 0.82 n.d. n.d. – – >20
6 35 1.09�0.01 0.82�0.01 0.75 0.0001 n.d. n.d. – – >20
7 36 3.04�0.02 2.98�0.04 0.98 0.23 6.69�0.11 9.29�0.17 1.39 0.0002 7.54�0.59
8 PMD 0.0024�0.0002 0.28�0.002 116 3.5×10  8 1.31�0.02 1.42�0.01 1.08 0.013 2.04�0.04
9 DA 0.082�0.006 0.89�0.05 10.8 0.0001 0.27�0.008 1.71�0.02 6.4 2×10  7 n.d.
WT=wild-type, PMD=pentamidine, DA=diminazene aceturate, DA-Res=diminazene-resistant cell line, RF= resistance factor being the ratio of EC50




3ChemMedChem 2021, 16, 1–7 www.chemmedchem.org © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH
These are not the final page numbers! ��
Wiley VCH Donnerstag, 02.09.2021
2199 / 218352 [S. 3/7] 1
The potential for cross-resistance with diamidines and
melaminophenyl arsenicals (MPAs; including melarsoprol, cyme-
larsan) is particularly problematic in the development of next-
generation amidine antiparasitics.[4] Resistance likely emerges
from active drug transport [e.g., TbAT1/P2 aminopurine
transporter;[29] High Affinity Pentamidine Transporter (TbAQP2)]
into the parasite’s interior.[30] Having studied the SAR of the
transporter-diamidine interactions, we hypothesized that
mono-N-arylation of the pentamidine scaffold would abolish
their ability to act as substrates for the T. brucei drug
transporters, and therefore would not display cross-resistance
with pentamidine and MPAs.[31] To test this hypothesis, 30–36
were also tested against a T. b. brucei clonal line, B48,[32] lacking
both the TbAT1/P2 and HAPT1/AQP2 transporters, and against
a diminazene-resistant T. congolense[11c] clone. Although minor
differences in drug sensitivity were observed (�50% of WT
EC50), these variations were trivial compared to the resistance
levels to pentamidine (116-fold) and diminazene (6.4-fold),
respectively. We therefore conclude that mono-N-arylated
pentamidine analogues are not cross-resistant with un-sub-
stituted diamidines, arising from differences in their mechanism
of uptake.
To gain further insights into the uptake of the mono-N-
arylated pentamidines, the fluorescent analogue (36) was used
to monitor uptake in each of the three parasite species in real-
time (Figure 1). In all three species, 36 was taken up rapidly
(3.3 μM and 10 μM), consistent with an EC50�3–7 μM against
the kinetoplastid species (Table 2). The rate of uptake of 36 was
Figure 1. Real time fluorescence development of 36 with bloodstream forms of WT T. b. brucei (A), bloodstream forms of WT T. congolense, (B) and
promastigotes of L. mexicana (C). Cells were incubated for 3 h in the presence of 36 at 0, 1, 3.3 or 10 μM, in the presence or absence of 10 μM pentamidine.
Measurements were taken at 2-minute intervals. A.U., artificial units of fluorescence intensity.
Figure 2. Selected immunofluorescence images of T. brucei labelled with a nuclear marker (Hoechst 33342), a dye for the mitochondrion (MitoTracker Green),
and with 36 (30 min exposure, [10 μM]) or not (control). Charts show the intensity levels of the DAPI and red filter channels measured in the nuclei and
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dose-dependent and showed an approximately 2.3–10-fold
higher rate at 10 μM [36] than for 3.3 μM after 30 min (Figure 1).
This shows that the uptake mechanism was not saturable in the
lower μM range, unlike TbAT1/P2 and HAPT/TbAQP2, which
display Km values of 0.26�0.03 and 0.036�0.06 μM, respec-
tively, for pentamidine.[30] Moreover, the rate of uptake of 36
was not substantially different in the presence of 10 μM
pentamidine (within 10% in all cases), clearly indicating that
uptake did not involve a high affinity pentamidine transporter.
Taken collectively, these data show that mono-N-arylated
analogues such as 36 evade known pentamidine transporters
TbAT1 and TbAQP2 in T. brucei.
One of the putative mechanisms of action of pentamidine is
the inhibition of replication via binding to A/T-rich sequences
of duplex DNA.[33] Indeed, selective accumulation of 36 to the
nucleus and kinetoplast of T. brucei was observed, as confirmed
by co-localization with Hoechst 33342 (Figure 2), consistent
with DNA binding. UV melt analyses were undertaken to
explore the ability of 33 and 36 to stabilize DNA duplexes
relative to pentamidine (Table S7, Figure S4). A 7.0 °C stabiliza-
tion of an A-tract duplex was observed for 33, relative to a
6.0 °C stabilization for pentamidine. Although a reduced level of
duplex stabilization was observed using 36 for the same
sequence (ΔTm 4.6 °C), both analogues exhibited a similar
binding bias for an A-tract duplex relative to a duplex
containing an alternating A-T sequence.[34] These data indicate
that the likely mechanism of action of these analogues is via
binding to DNA duplexes with a selectivity profile similar to
that observed for pentamidine. The stronger DNA binding of 33
correlated with its stronger anti-kinetoplastid activity compared
to 36.
In summary, we have developed a general approach to
prepare mono-N-arylated amidines from mono- and bisamidine
substrates based on Chan-Lam cross-coupling methodology.
During our optimization phase, key mechanistic insights into Cu
intermediates pertinent to the Chan-Lam reaction were identi-
fied, and the procedure was broadly applicable to the formation
of mono-N-arylated substrates. This methodology was used to
directly prepare mono-N-arylated analogues of pentamidine,
which displayed promising in vitro activity against three species
of kinetoplast parasites of clinical and veterinary importance.
Most importantly, the mono-N-arylated analogues were not
cross-resistant with pentamidine and diminazene, bypassing
known drug transporters. In addition, 36 accumulated rapidly in
all three kinetoplastid species and localized to the parasite
nucleus and kinetoplast, consistent with a putative mechanism
of action being a DNA minor groove binder. These findings
highlight that the potential utility of mono-N-arylation of
diamidines, and potentially their expansion to guanidine
analogues,[35] as an emerging class of therapeutic agents against
neglected parasitic diseases.
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COMMUNICATIONS
Accessing antiparasitic amidines: A
selective mono-N-arylation strategy of
amidines under Chan-Lam conditions
was used to access the first mono-N-
arylated analogues of pentamidine.
Sub-micromolar activity against kinet-
oplastid parasites was observed for
several analogues with no cross-resist-
ance in pentamidine and diminazene-
resistant trypanosome strains and
against Leishmania mexicana. This
work highlights the potential of Chan-
Lam mono-N-arylation to develop
therapeutic leads against diamidine-
resistant trypanosomiasis and leish-
maniasis.
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